Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-label Phase III Clinical Trial to Evaluate Efficacy and Safety of the Cellgram-LC in Patients With Alcoholic Liver Cirrhosis

NCT04689152 is registered in ClinicalTrials.gov with Pharmicell Co., Ltd. as lead sponsor.

NCT NCT04689152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04689152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-label Phase III Clinical Trial to Evaluate Efficacy and Safety of the Cellgram-LC in Patients With Alcoholic Liver Cirrhosis
Lead sponsor
Pharmicell Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
April 19, 2021
Completion date
December 1, 2029
Enrollment
200 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

alcoholic cirrhosis